AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery

RecruitingNAAges 18 Years - anyAllFujian Medical University
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to learn if a technique called remote ischemic preconditioning (RIPC) helps protect organs during emergency surgery for acute type A aortic dissection (ATAAD). The main questions it aims to answer are: Does RIPC reduce the risk of major complications after surgery, such as heart, brain, or kidney problems? Is RIPC safe to use during emergency ATAAD surgery? Researchers will compare the RIPC group to a control group (who will receive a placebo) to see if RIPC can reduce complications after surgery. Participants will: Receive either RIPC or a sham intervention during their surgery. Be monitored for up to 30 days after surgery for complications. Have follow-up visits at 3 months, 1 year, and then yearly for up to 5 years to track their recovery.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age ≥18 years; 2. Acute type A aortic dissection requiring emergency surgery within 14 days of symptom onset; 3. Written informed consent provided by the participant or a legally authorized representative; 4. Willingness to comply with study follow-up. Exclusion Criteria: 1. Traumatic or iatrogenic aortic dissection; 2. Previous open cardiac or thoracic aortic surgery; 3. Persistent deep coma (Glasgow Coma Scale score ≤8), abdominal compartment syndrome, preoperative mechanical circulatory support, or norepinephrine-equivalent dose \>0.1 μg/kg/min; 4. Estimated glomerular filtration rate \<30 mL/min/1.73 m², total bilirubin \>342 μmol/L, or international normalized ratio \>2.0; 5. Evidence of ischemia in the limb planned for intervention, including decreased skin temperature, pain, or pallor, with or without sensory disturbance, paralysis, or diminished or absent peripheral pulses; severe deformity of the limb; or a history of arterial or venous surgery at the planned intervention site; 6. Peripheral arterial disease involving the limbs, Raynaud phenomenon, active phlebitis, or a history of lower-extremity deep vein thrombosis; 7. Current use of sulfonylureas or nicorandil; 8. Expected survival \<1 year; 9. Concurrent participation in another clinical trial that has not yet reached its primary endpoint; 10. Pregnancy or breastfeeding; 11. Immunodeficiency, a known bleeding or coagulation disorder, sickle cell anemia, or active or uncontrolled infection; 12. Any other condition considered unsuitable for enrollment by the investigator
💊

What it tests

  • Remote ischemic preconditioning (RIPC)
📍

Where

16 sites
The First Affiliated Hospital of Anhui Medical University
Hefei, China
Fujian Medical University Union Hospital
Fuzhou, China
The First Affiliated Hospital of Xiamen University
Xiamen, China
Xiamen Cardiovascular Hospital, Xiamen University
Xiamen, China
The First Affiliated Hospital of Sun Yat-Sen University
Guangzhou, China
The First Affiliated Hospital of Harbin Medical University
Harbin, China
The Fourth Hospital of Harbin Medical University
Harbin, China
Henan Provincial Chest Hospital
Zhengzhou, China

…and 8 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy